Kidney Cancer | Tumor

Women With Diabetes May Face Increased Kidney Cancer Risk

July 26th 2021, 9:00pm

Article

Post-menopausal women may be at an increased risk for kidney cancer if they are diagnosed with type 2 diabetes.

Inequality in Kidney Cancer Treatment Affects Decision-Making

July 19th 2021, 9:00pm

Article

The risk for under- or over-treatment for kidney cancer may be higher in women, in addition to Black and Hispanic patients.

Minnesota Congressman Jim Hagedorn’s Cancer Returned, A Three-time Survivor Plans to Bike 100 Miles and More

July 9th 2021, 3:00pm

Article

From the recurrence of congressman Jim Hagedorn’s kidney cancer to a 100-mile bike race for charity, here’s what’s happening in the cancer landscape this week.

Lenvima-Keytruda Combo Shows Superior Benefit Over Sutent Across Several Subgroups of Patients with Kidney Cancer

June 28th 2021, 6:00pm

Article

The combination of Lenvima and Keytruda was associated with improvements in survival and response rates over Sutent alone in various subgroups of patients with advanced renal cell carcinoma.

Novel Drug Induces Robust Responses in von-Hippel Lindau Disease-Associated Kidney Cancer

June 24th 2021, 6:00pm

Article

At a median follow-up of almost two years, 88.5% of patients remained on study treatment.

Friday Frontline: Man With Late-Stage Cancer Gets Matching Tattoos with Strangers, 78-Year-Old Cancer Survivor Earns Black Belt

June 18th 2021, 3:00pm

Article

From a man with late-stage cancer who has matching tattoos with over 400 strangers to a 78-year-old cancer survivor getting his black belt in Taekwondo, here’s what’s happening in the cancer landscape this week.

Keytruda-Inlyta Combo Continues to Improve Survival in Kidney Cancer

June 10th 2021, 6:00pm

Article

Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.

Fotivda Nearly Doubles Duration of Response Compared With Nexavar in Metastatic Kidney Cancer

June 6th 2021, 6:00pm

Article

In patients with metastatic renal cell carcinoma whose disease failed to respond to two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.

Keytruda After Surgery Significantly Improves Survival in Patients with Kidney Cancer

June 4th 2021, 6:30pm

Article

Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.

FDA Grants Keytruda-Lenvima Combo Priority Review for Treatment of Advanced Kidney Cancer and Endometrial Cancer

May 6th 2021, 1:52pm

Article

The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.